Vivos Therapeutics (VVOS) Other Non-Current Assets (2019 - 2026)

Vivos Therapeutics (VVOS) has reported Other Non-Current Assets for 8 consecutive years, with $272000.0 the latest figure, recorded in Q2 2026.

• On a quarterly basis, Other Non-Current Assets rose 6.67% year-over-year to $272000.0 in Q2 2026; TTM through Jun 2026 was $272000.0, a 6.67% increase from a year earlier, with the FY2025 full-year figure at $228000.0, up 5.56% from the prior year.
• Other Non-Current Assets was $272000.0 for Q2 2026 at Vivos Therapeutics, up from $254000.0 in the prior quarter.
• Over five years, Other Non-Current Assets peaked at $374000.0 in Q4 2022 and troughed at $211000.0 in Q3 2025.
• A 5-year average of $289666.7 and a median of $291500.0 in 2023 frame the typical range for Other Non-Current Assets.
• Across the five-year window, Other Non-Current Assets plunged 30.19% in 2025 and advanced 18.14% in 2026, its largest moves.
• Over 5 years, Other Non-Current Assets stood at $374000.0 in 2022, then retreated by 17.91% to $307000.0 in 2023, then decreased by 29.64% to $216000.0 in 2024, then grew by 5.56% to $228000.0 in 2025, then grew by 19.3% to $272000.0 in 2026.
• The last three Other Non-Current Assets figures came in at $272000.0 (Q2 2026), $254000.0 (Q1 2026), and $228000.0 (Q4 2025), per Business Quant data.